Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen
Loading...
Date
Authors
Singh, Sanjay
Gumbo, Tawanda
Alffenaar, Jan-Willem
Boorgula, Gunavanthi D.
Shankar, Prem
Thomas, Tania A.
Dheda, Keertan
Malinga, Lesibana Anthony
Raj, Prithvi
Aryal, Santosh
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Please read abstract in the article.
Description
DATA AVAILABILITY STATEMENT : Upon a reasonable request, the raw data for the results presented in the manuscript are available from the corresponding author.
Keywords
Beta-lactams, Pharmacokinetics, Pharmacodynamics, Tuberculosis (TB), β-lactamase inhibitors (BLIs), Bedaquiline-pretonamid-linezolid (BPaL), Hollow fiber model system, Multidrug-resistant tuberculosis (MDR-TB), Mycobacterium tuberculosis (MTB), SDG-03: Good health and well-being
Sustainable Development Goals
SDG-03:Good heatlh and well-being
Citation
Singh, S., Gumbo, T., Alffenaar, J.-W. et al. 2023, 'Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen', International Journal of Antimicrobial Agents, vol. 62, no. 6, art. 106968, pp. 1-8, doi : 10.1016/j.ijantimicag.2023.106968.